Logo

Novartis Halts Clinical Trial Evaluating Hydroxychloroquine Against COVID-19 Due to Slow Enrollment

Share this

Novartis Halts Clinical Trial Evaluating Hydroxychloroquine Against COVID-19 Due to Slow Enrollment

Shots:

  • Novartis has discontinued its clinical trial HCQs due to feasibility of recruitment. The recruitment challenge has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19
  • Novartis will continue to supply HCQ for ongoing IITs on government request globally and will continue to monitor ongoing guidance from health authorities on the further study of HCQ- as well as the decision by the US FDA to stop the EUA of HCQ for COVID-19 treatment
  • Novartis will continue to collaborate to find answers for COVID-19 through various partnerships with multi-stakeholder external consortia

Click here to read full press release/ article 

 Ref: Novartis | Image: Novartis 

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions